At the tract level, higher smoking prevalence was associated with higher prevalence of asthma, COPD, and CHD (Figure, B) . For instance, a change from the 10th to the 90th percentile of smoking prevalence (from 10.7% to 27.6%) was associated with a 38.9% (95% CI, 38.1%-39.5%) increase in the prevalence of asthma, a 120.2% (95% CI, 116.6%-124.0%) increase in the prevalence of COPD, and a 26.6% (95% CI, 24.5%-29.0%) increase in the prevalence of CHD.
Utilization of Long-Acting Reversible Contraceptives in the United States After vs Before the 2016 US Presidential Election
Soon after the US presidential election on November 8, 2016, media and industry reports described an increase in utilization of long-acting reversible contraceptive (LARC) methods (intrauterine devices and implants).
1 Proposed reasons included women's concerns about contraceptive access should the Patient Protection and Affordable Care Act (ACA) be repealed during the Trump Administration. These reports, however, were descriptive and did not control for seasonal or secular trends. Using data from a large sample of commercially insured women, we sought to assess whether there was an increase in LARC utilization among commercially insured women during the 30 days after the election, compared with the 30 days before the election and the same period in 2015.
Methods | Using the IBM/Truven MarketScan Analytics Commercial Claims and Encounters Database, we studied women aged 18 to 45 years enrolled in commercial insurance during the 30 business days before and after November 8 in 2015 or 2016 who had at least 12 months of continuous enrollment. We used billing codes (eTable in the Supplement) to calculate daily LARC insertion rates during the 30 business days before (inclusive of November 8) and 30 days after November 8 in 2015 and 2016. To account for secular trends, we estimated changes in daily LARC insertions using a difference-in-differences generalized linear model with a Poisson distribution and log link function that compared the change in probability of LARC insertion during the 30 business days before vs after November 8, 2016, with the change in the comparable period in 2015. With person-day as the unit of analysis, we adjusted for age group, region, relationship to the insured individual, and plan type (Table) and accounted for clustering by individuals (because individuals contributed information for multiple time points). Wald tests were used to calculate the P values. We considered a 2-sided P < .05 to indicate statistical significance. The Harvard Medical School Office of Human Research Administration exempted the study from human subject review; therefore, patient consent was not required. All data were deidentified. (Table) . In 2015, the mean adjusted
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Letters daily LARC insertion rate during the 30 business days before and inclusive of November 8 was 12.9 per 100 000 women vs 13.7 per 100 000 women during the subsequent 30 business days. The comparable mean adjusted daily LARC insertion rates before and after the 2016 presidential election were 13.4 per 100 000 women and 16.3 per 100 000 women ( Figure) , an increase of 21.6%. The adjusted difference-indifference rate was 2.1 insertions per 100 000 women per day (P < .001).
Discussion | We observed a significant increase in LARC insertions among commercially insured women during the 30 business days after the 2016 presidential election, adjusting for secular and seasonal trends and patient characteristics. If our findings were projected to the approximately 33 million women in the United States aged 18 to 45 years in 2016 with employersponsored health insurance, this rate would correspond to approximately 700 additional insertions per day in association with the 2016 election, above the approximately 4716 insertions per day that would have been otherwise predicted.
Long-acting reversible contraceptive methods are highly effective at preventing pregnancy for up to 12 years and are widely recommended as first-line contraception.
2 Longacting reversible contraceptives remain underused in the United States. 3 In 2012, the ACA eliminated cost-sharing for contraception for most women with private health insurance. Median out-of-pocket costs for an intrauterine device decreased from $40 to $0, 4 and LARC insertions increased.
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Our study has limitations. We lacked information about important covariates, including race/ethnicity; we studied a short period after the election; and we only studied women with commercial insurance. Our findings may not generalize to women with public insurance or no health insurance. We could not determine whether the increase in LARC insertions was sustained or evaluate its public health significance. Although 2017 data were not yet available at the time of our study, we could repeat this analysis for that year.
The ACA's contraceptive coverage mandate is an important strategy to reduce unintended pregnancies. The Trump Administration has weakened this mandate. 6 Our findings could reflect a response to fears of losing contraceptive coverage because of President Trump's opposition to the ACA or an association of the 2016 election with reproductive intentions or LARC awareness. Our findings also suggest that women with commercial health insurance value contraceptive coverage and that concerns about potential reductions in access or coverage may affect their contraceptive choices. 
Trends in Testosterone Prescribing for Age-related Hypogonadism in Men With and Without Heart Disease
Signals of cardiovascular risk from off-label prescription testosterone use began with the early termination of a placebocontrolled trial in frail, older men. Basaria et al 1 revealed more cardiovascular events among men randomized to receive testosterone than among men randomized to receive placebo. Some observational studies reinforced these concerns for cardiovascular risk. 2, 3 In 2014, the US Food and Drug Administration (FDA) issued a safety communication about testosterone drugs, and the Endocrine Society expressed particular concern about testosterone use by men with heart disease. 4, 5 In 2015, the FDA revised testosterone labels, highlighting the lack of efficacy evidence for agerelated hypogonadism and adding a warning about possible increased cardiovascular risk.
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In this study, we explored trends in testosterone use among Medicare-insured men with and without coronary artery disease (CAD) to see how prescribing changed in response to concerns.
Methods | This study was approved by the institutional review board at Dartmouth College. Patient consent was waived by this institutional review board because the research could not be practicably conducted without a waiver and because the risks to individuals were deemed reasonable in relation to the anticipated advantages.
Using a 40% random sample of Medicare fee-for-service administrative data from January 1, 2007, to December 31, 2016, we created annual cohorts of men aged 50 years or older, with and without a same-year CAD diagnosis, and measured testosterone prescription fills under Medicare Parts B and D. Use was considered on-label if patients had a same-year diagnosis for any indicated condition (eg, Klinefelter syndrome) or off-label if patients did not have a same-year diagnosis.
We calculated the percentage of men who received prescription testosterone, using direct adjustment for national rates and logistic regression for hospital referral region rates (adjusting for age, race, Part D low-income subsidy, and Medicaid eligibility). We limited regional analyses to the 273 hospital referral regions with 500 or more beneficiaries in each annual cohort. Testosterone expenditures were estimated by multiplying the observed reimbursement rate (from the 40% sample) by 2.5. Secondary and sensitivity analyses were included for Part D recipients subject to prior authorization, age-stratified models (<65 years vs ≥65 years), and cohorts in which a CAD diagnosis or a testosteroneapproved indication was determined with a 3-year (rather than same-year) look-back analysis.
Results | The annual cohorts ranged from 1.8 to 3.1 million, representing 10% to 12% of all fee-for-service male Medicare enrollees older than 50 years. Annual CAD cohorts ranged from 629 823 (33.9% of the full cohort) in 2007 to 1 017 484 (32.3% of the full cohort) in 2016. The mean (SD) age was 71.2 (9.0) years. The adjusted percentage of all men who received on-label prescription testosterone ranged from 0.2% (3 681) to 0.3% (8 861); off-label prescription testosterone use peaked in 2013 at 3.2% of the cohort (29 144) with CAD and 2.4% of the cohort (45 029) without CAD.
Testosterone use was consistently higher for men with CAD than for men without CAD, 2.0% and 1.6% of the cohorts, respectively, in 2016, for example (Figure 1) . Sensitivity analyses replicated the main analyses. Annual testosterone spending was $108 million in 2007 and $402 million in 2016. The proportion of men with Part D prescription testosterone fills subject to prior authorization was 21% (13 685) in 2012 and 49% (31 462) in 2016. Regional testosterone use varied substantially. Use was consistently twice the national rate in 4 regions but was less than half the national rate in 14 regions. For example, the national rate in 2012 was 2.0% in 4 regions with high use, and in 2016, use ranged from 4.4% to 7.0% of the full cohort; in 14 regions with low use in 2012, the use ranged from 0.5% to 1.0% in 2016 (Figure 2) .
